Sedor Pharmaceuticals gets FDA approval for SESQUIENT to treat status epilepticus

This article was originally published here

According to Neurocritical Care Society Guidelines, status epilepticus, which is classified as a single epileptic seizure lasting more than five minutes or two or more seizures within a

The post Sedor Pharmaceuticals gets FDA approval for SESQUIENT to treat status epilepticus appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply